I'm about to have my first baby. How much maternity leave must my employer allow me? Ask Soma
Q: I am having my first child soon and I am worried about how much time I will get to stay home from work with my baby.
What are my maternity leave entitlements?
A: Congratulations! Becoming a first-time parent can be a nerve-racking experience.
Here is what you need to know.
The Employment Standards Act (ESA) states that pregnant employees in Ontario have a right to take up to 17 weeks of unpaid time off for pregnancy leave.
ARTICLE CONTINUES BELOW
Additionally, birth mothers who take pregnancy leave are also entitled to up to 61 weeks of unpaid parental leave once the child is born.
The ESA also outlines that birth mothers who do not take pregnancy leave and all other new parents (including adoptive) are entitled to up to 63 weeks parental leave.
However, in order to qualify for pregnancy or parental leave, an employee must have started employment in Ontario at least 13 weeks before their baby's due date.
Business
Opinion
Soma Ray-Ellis: Is my employer allowed to monitor me in the workplace digitally and by video surveillance? Ask Soma
When you're at work, your privacy is limited — your employer can monitor shared spaces and
An employee is required to give their employer at least two weeks' written notice before beginning pregnancy leave.
They must also provide a certificate from a medical practitioner (which can include a doctor, a midwife, or a nurse practitioner) stating the baby's due date if their employer requests it.
While pregnancy and parental leave offered through the ESA are both unpaid, an employee may be entitled to paid benefits through the federal Employment Insurance (EI) program.
ARTICLE CONTINUES BELOW
ARTICLE CONTINUES BELOW
EI maternity benefits are offered to biological mothers (or surrogates) who cannot work because they are pregnant or have recently given birth.
The program provides a maximum of 15 weeks of EI maternity benefits.
The 15 weeks can start as early as 12 weeks before the expected date of birth and can end as late as 17 weeks after the date of birth.
There are also standard and extended parental leave benefits available through EI.
EI legislation states that standard benefits can be paid for a maximum of 35 weeks and must be claimed within a 52-week period after the week the child was born or placed for the purpose of adoption.
These benefits are available to any biological, adoptive, or legally recognized parents at a weekly benefit rate of 55% of the claimant's average weekly insurable earnings up to a maximum insurable amount of $65,700.
The 35 weeks of standard parental benefits can be shared by two parents.
The extended parental benefits are for a maximum of 61 weeks which must be used within a 78-week period (18 months).
ARTICLE CONTINUES BELOW
ARTICLE CONTINUES BELOW
To be eligible for EI maternity or parental benefits, you must be employed in insurable employment in Canada, your normal weekly earnings are reduced by more than 40%, and you have accumulated at least 600 hours of insurable employment in the 52 weeks before the start of your claim.
Business
Opinion
Soma Ray-Ellis: Show me the money! How will Ontario's new wage transparency law affect me? Ask Soma
Starting next year, writes Soma Ray-Ellis, new Ontario pay transparency laws will require every
Keep in mind that your job security is legally protected while you are on leave, and an employer cannot penalize an employee for taking pregnancy/parental leave.
In fact, the ESA outlines that employees on leave have the right to continue in certain benefit plans and earn seniority.
In most cases, employees must be given back their old job at the end of their pregnancy and/or parental leave.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
17 hours ago
- Toronto Star
I'm about to have my first baby. How much maternity leave must my employer allow me? Ask Soma
Q: I am having my first child soon and I am worried about how much time I will get to stay home from work with my baby. What are my maternity leave entitlements? A: Congratulations! Becoming a first-time parent can be a nerve-racking experience. Here is what you need to know. The Employment Standards Act (ESA) states that pregnant employees in Ontario have a right to take up to 17 weeks of unpaid time off for pregnancy leave. ARTICLE CONTINUES BELOW Additionally, birth mothers who take pregnancy leave are also entitled to up to 61 weeks of unpaid parental leave once the child is born. The ESA also outlines that birth mothers who do not take pregnancy leave and all other new parents (including adoptive) are entitled to up to 63 weeks parental leave. However, in order to qualify for pregnancy or parental leave, an employee must have started employment in Ontario at least 13 weeks before their baby's due date. Business Opinion Soma Ray-Ellis: Is my employer allowed to monitor me in the workplace digitally and by video surveillance? Ask Soma When you're at work, your privacy is limited — your employer can monitor shared spaces and An employee is required to give their employer at least two weeks' written notice before beginning pregnancy leave. They must also provide a certificate from a medical practitioner (which can include a doctor, a midwife, or a nurse practitioner) stating the baby's due date if their employer requests it. While pregnancy and parental leave offered through the ESA are both unpaid, an employee may be entitled to paid benefits through the federal Employment Insurance (EI) program. ARTICLE CONTINUES BELOW ARTICLE CONTINUES BELOW EI maternity benefits are offered to biological mothers (or surrogates) who cannot work because they are pregnant or have recently given birth. The program provides a maximum of 15 weeks of EI maternity benefits. The 15 weeks can start as early as 12 weeks before the expected date of birth and can end as late as 17 weeks after the date of birth. There are also standard and extended parental leave benefits available through EI. EI legislation states that standard benefits can be paid for a maximum of 35 weeks and must be claimed within a 52-week period after the week the child was born or placed for the purpose of adoption. These benefits are available to any biological, adoptive, or legally recognized parents at a weekly benefit rate of 55% of the claimant's average weekly insurable earnings up to a maximum insurable amount of $65,700. The 35 weeks of standard parental benefits can be shared by two parents. The extended parental benefits are for a maximum of 61 weeks which must be used within a 78-week period (18 months). ARTICLE CONTINUES BELOW ARTICLE CONTINUES BELOW To be eligible for EI maternity or parental benefits, you must be employed in insurable employment in Canada, your normal weekly earnings are reduced by more than 40%, and you have accumulated at least 600 hours of insurable employment in the 52 weeks before the start of your claim. Business Opinion Soma Ray-Ellis: Show me the money! How will Ontario's new wage transparency law affect me? Ask Soma Starting next year, writes Soma Ray-Ellis, new Ontario pay transparency laws will require every Keep in mind that your job security is legally protected while you are on leave, and an employer cannot penalize an employee for taking pregnancy/parental leave. In fact, the ESA outlines that employees on leave have the right to continue in certain benefit plans and earn seniority. In most cases, employees must be given back their old job at the end of their pregnancy and/or parental leave.
CBC
15-04-2025
- CBC
B.C. NDP introduce bill to eliminate mandatory sick notes for short-term work absences
British Columbia's labour minister is moving to eliminate sick note requirements for short-term absences from work in an effort to give doctors and nurses more time with patients. The province said Tuesday that Jennifer Whiteside introduced Bill 11, which would amend the Employment Standards Act to clarify when employers can and cannot request a sick note from workers. In December, Dr. Joss Reimer, president of the Canadian Medical Association, called for reducing mandatory sick notes. Canadian doctors spend an estimated 1.5 million hours writing sick notes every year, according to the association. The B.C. College of Family Physicians made a similar plea in January. Right now, B.C. workers who have been employed with an organization for more than 90 days are entitled to up to five paid and three unpaid days of job-protected illness or injury leave — often referred to as sick leave or sick days — per calendar year. According to the provincial website, employers can request "reasonably sufficient proof" of illness, which can include a doctor's note, a receipt from a drugstore or pharmacy or a medical bracelet from the hospital. The changes in Bill 11 will clarify that employers can't specifically request — and employees are not required to provide — a sick note written by a physician, nurse practitioner or registered nurse as proof that the employee's short-term absence from work was related to illness or injury. A firm set of regulations will be established with input from stakeholders, the province said, and will define what constitutes a short-term absence. Eliminating sick note requirements was a key promise in the B.C. NDP's provincial election campaign last fall. "Requiring a sick patient to leave their home can do more harm than good," Dr. Charlene Lui, the association's president, said in a media release. "It can delay the patient's recovery time, it can put other patients at risk of infection, and can cause sicker patients to wait longer to see the doctor." The province expects the new rules to be in place prior to the fall respiratory illness season.
Globe and Mail
21-01-2025
- Globe and Mail
Myelodysplastic Syndrome Therapeutics Market Size in the 7MM was ~USD 2,800 Million in 2023, is expected to grow by 2034
DelveInsight's"Myelodysplastic Syndrome Market Insight, Epidemiology, and Market Forecast – 2034" report delivers an in-depth understanding of the Myelodysplastic Syndrome historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Unlock key insights into the Myelodysplastic Syndrome Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Myelodysplastic Syndrome Market Size Key Takeaways from the Myelodysplastic Syndrome Market Report In January 2025:- Keros Therapeutics Inc.:- This study (KER-050-D301) is evaluating the efficacy and safety of elritercept (KER-050) versus placebo in adult participants with transfusion-dependent anemia with very low, low, or intermediate risk MDS, or more recently defined as myelodysplastic neoplasms, with or without ring sideroblasts. The study is divided into the Screening Period, Double-blind Treatment Period, Safety Follow-Up Period and Long-term Follow-up Period. In January 2025:- Bristol-Myers Squibb- The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD). In the 7MM, the US accounted for the highest Myelodysplastic Syndrome incident cases in 2023, with around 21,000 cases; these numbers are expected to increase during the forecast period. Among the age-specific cases, the cases from the age group 80+ accounted for the highest incident cases in 2023 in the US, with nearly 40% of total cases. Among the subtype-specific cases, RAEB/MDS-EB accounted for the highest number in the US in 2023. Amongst EU4 and the UK, Germany accounted for the highest incident cases, followed by France, while Spain occupied the bottom of the ladder in 2023. The leading Myelodysplastic Syndrome Companies such as Bristol-Myers Squibb, Astex Pharmaceutical, Taiho Oncology, Fibrogen, AbbVie, Gilead Sciences, Novartis, Syros Pharmaceuticals, Takeda, Pfizer, Geron Corporation, Karyopharm Therapeutics, Antengene Corporation, BerGenBio ASA, Jazz Pharmaceuticals, Aprea Therapeutics, Sanofi, Medac and others. Promising Myelodysplastic Syndrome Therapies such as Deferasirox, Tebapivat, KER-050, Luspatercept, Epoetin Alfa, and others. Stay ahead in the competitive landscape of the Myelodysplastic Syndrome Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Myelodysplastic Syndrome Treatment Market Size Myelodysplastic Syndrome Epidemiology Segmentation in the 7MM Total Incident Population of Myelodysplastic Syndrome Age-specific Incident Population of Myelodysplastic Syndrome Subtype-specific Incident Population of Myelodysplastic Syndrome Risk-specific Incident Population of Myelodysplastic Syndrome Mutation-specific Incident Population of Myelodysplastic Syndrome Download the report to understand which factors are driving Myelodysplastic Syndrome epidemiology trends @ Myelodysplastic Syndrome Prevalence Myelodysplastic Syndrome Marketed Drugs VIDAZA (azacitidine): Bristol Myers Squibb VIDAZA is a pyrimidine nucleoside analog of cytidine. VIDAZA is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. The concentration of azacitidine required for maximum inhibition of DNA methylation in vitro does not cause major suppression of DNA synthesis. It was first approved by the US FDA in May 2004 for the Myelodysplastic Syndrome treatment. DACOGEN (decitabine): Johnson & Johnson DACOGEN is a nucleoside metabolic inhibitor indicated for the treatment of adult patients with myelodysplastic syndromes including previously treated and untreated, de novo and secondary MDS. Decitabine-induced hypomethylation in neoplastic cells may restore normal function to genes that are critical for the control of cellular differentiation and proliferation. In rapidly dividing cells, the cytotoxicity of decitabine may also be attributed to the formation of covalent adducts between DNA methyltransferase and decitabine incorporated into DNA. Non-proliferating cells are relatively insensitive to decitabine. It was first approved by the US FDA in May 2006. Myelodysplastic Syndrome Emerging Drugs Venetoclax: Abbvie Venetoclax by Abbvie is a first-in-class targeted medicine designed to selectively bind and inhibit the B-cell lymphoma-2 (BCL-2) protein. Currently, the drug is being investigated in a Phase III trial to treat adult patients with newly diagnosed higher-risk Myelodysplastic Syndrome. Moreover, in July 2021, the combination was granted Breakthrough Therapy Designation in higher risk Myelodysplastic Syndrome. Tamibarotene: Syros Pharmaceuticals Tamibarotene is an oral selective retinoic acid receptor alpha (RARA) agonist being developed for genomically defined subsets of patients whose disease is characterized by the overexpression of the RARA gene. Approximately 50% of Myelodysplastic Syndrome patients and 30% of AML patients have RARA overexpression. When RARA is expressed more than its tightly controlled natural ligand, cells in the bone marrow may not differentiate into healthy myeloid cells, which can lead to hematological malignancies. However, when oral tamibarotene is administered, tamibarotene binds to RARα, allowing for the restoration of gene expression and myeloid differentiation. It is currently being investigated in the Phase III SELECT-MDS-1 trial in newly diagnosed higher-risk myelodysplastic syndrome patients with RARA overexpression. Discover the future of Myelodysplastic Syndrome Treatments with DelveInsight's latest market report. Get expert insights and forecasts—download now! @ Myelodysplastic Syndrome Market Drivers and Barriers Myelodysplastic Syndrome Drugs Market Insights There is a vast pipeline of targeted agents under pre-clinical and clinical development, potentially able to modify the natural history of the diverse disease spectrum of MDS. The B-cell leukemia/lymphoma-2 (BCL-2) inhibitor, venetoclax is to date one of the most potent anti-apoptotic inhibitors, representing a novel promising agent. This small molecule blocks the binding of BH3 proteins to BCL-2, allowing the activation of BCL2 Antagonist/Killer/BCL2 associated X on the surface of mitochondria leading to cell death of cancer cells because of the release of cytochrome C through a mitochondrial outer membrane permeabilization (MOMP) process. IDH1 and IDH2 inhibitors have also recently shown an acceptable ORR in different clinical trials. FLT3 inhibitors represent another important potential group of targeted compounds in MDS patients harboring FLT3 mutations. Myelodysplastic Syndrome Market Outlook While for more than a decade the therapeutic scenario of Myelodysplastic Syndrome syndromes has been dominated by very few available regimens associated with dismal results, especially for patients with higher-risk disease and who failed HMAs, in the last 2 years there was a flow of an incredible variety of new targeted agents and investigational approaches that possibly will reach the clinical setting in short time. If currently available therapies still include HMAs, lenalidomide, growth factor support, chemotherapy, and allo-HSCT, there is now the possibility to choose among new investigational treatments rationally designed to exert targeted actions and increase the response rates in categories of patients that so far remained precision drug-orphans. Explore the dynamics of the Myelodysplastic Syndrome Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Myelodysplastic Syndrome Ongoing Clinical Trials Analysis Scope of the Myelodysplastic Syndrome Market Report Coverage- 7MM Study Period- 2020-2034 Myelodysplastic Syndrome Companies- Bristol-Myers Squibb, Astex Pharmaceutical, Taiho Oncology, Fibrogen, AbbVie, Gilead Sciences, Novartis, Syros Pharmaceuticals, Takeda, Pfizer, Geron Corporation, Karyopharm Therapeutics, Antengene Corporation, BerGenBio ASA, Jazz Pharmaceuticals, Aprea Therapeutics, Sanofi, Medac and others. Myelodysplastic Syndrome Therapies- Deferasirox, Tebapivat, KER-050, Luspatercept, Epoetin Alfa, and others. Myelodysplastic Syndrome Therapeutic Assessment: Myelodysplastic Syndrome Current Marketed and Myelodysplastic Syndrome Emerging Therapies Myelodysplastic Syndrome Market Dynamics: Myelodysplastic Syndrome market drivers and Myelodysplastic Syndrome market barriers Myelodysplastic Syndrome Unmet Needs, KOL's views, Analyst's views, Myelodysplastic Syndrome Market Access and Reimbursement Table of Content 1 Key Insights 2 Report Introduction 3 Executive Summary of Myelodysplastic Syndrome (MDS) 4 Myelodysplastic Syndrome (MDS) Market Overview at a Glance 5 Key Events 6 Epidemiology and Market Forecast Methodology 7 Disease Background and Overview 8 Diagnostic Algorithm 9 British Society for Hematology guidelines for the Diagnosis and Evaluation of Prognosis of Adult MDS 10 Treatment 11 National Comprehensive Cancer Network recommendations for myelodysplastic syndrome 12 Myelodysplastic Syndromes: ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up 13 JSH Practical Guidelines for MDS 14 British Society for Hematology Guidelines for the Management of Adult Myelodysplastic Syndromes 15 Treatment Algorithm 16 Epidemiology and Patient Population 17 Organizations contributing toward Myelodysplastic Syndrome 18 Patient Journey 19 Marketed Drugs 20 Emerging Therapies 21 Myelodysplastic Syndrome: Seven Major Market Analysis 22 Unmet Need 23 SWOT Analysis 24 KOL Views 25 Market Access and Reimbursement 26 Appendix 27 DelveInsight Capabilities 28 Disclaimer 29 About DelveInsight About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 919650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
